United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole 100 mg - fluconazole tablets, usp are indicated for the treatment of: - vaginal candidiasis (vaginal yeast infections due to candida ). - oropharyngeal and esophageal candidiasis. in open noncomparative studies of relatively small numbers of patients, fluconazole tablets, usp were also effective for the treatment of candida urinary tract infections, peritonitis and systemic candida infections including candidemia, disseminated candidiasis and pneumonia. - cryptococcal meningitis. before prescribing fluconazole tablets, usp for aids patients with cryptococcal meningitis, please see clinical studies section. studies comparing fluconazole to amphotericin b in non-hiv infected patients have not been conducted. prophylaxis. fluconazole tablets, usp are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole 100 mg - fluconazole tablets, usp are indicated for the treatment of: - vaginal candidiasis (vaginal yeast infections due to candida ). - oropharyngeal and esophageal candidiasis. in open noncomparative studies of relatively small numbers of patients, fluconazole tablets, usp were also effective for the treatment of candida urinary tract infections, peritonitis and systemic candida infections including candidemia, disseminated candidiasis and pneumonia. - cryptococcal meningitis. before prescribing fluconazole tablets, usp for aids patients with cryptococcal meningitis, please see clinical studies section. studies comparing fluconazole to amphotericin b in non-hiv infected patients have not been conducted. prophylaxis. fluconazole tablets, usp are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - fluconazole - capsule, hard - 50 milligram(s) - triazole derivatives; fluconazole

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - fluconazole - capsule, hard - 150 milligram(s) - triazole derivatives; fluconazole

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - fluconazole - capsule, hard - 150 milligram(s) - triazole derivatives; fluconazole

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - fluconazole - capsule, hard - 50 milligram(s) - triazole derivatives; fluconazole

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - fluconazole - capsule, hard - 150 milligram(s) - triazole derivatives; fluconazole

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - fluconazole - capsule, hard - 50 milligram(s) - triazole derivatives; fluconazole

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - fluconazole 100mg; fluconazole 100mg - capsule - 100 mg - active: fluconazole 100mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate patent blue v pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide active: fluconazole 100mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate maize starch patent blue v sodium laurilsulfate tekprint black sw-9008 tekprint black sw-9009 titanium dioxide - 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseminated candidiasis and other forms of invasive candidal infection including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplant 6. fluconazole 50 mg & 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 150 mg - capsule, hard - excipient ingredients: brilliant blue fcf; pregelatinised maize starch; gelatin; colloidal anhydrous silica; magnesium stearate; sodium lauryl sulfate; purified talc; lactose monohydrate; purified water; titanium dioxide - fluconazole, given orally, is indicated for treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note. data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aquired immune deficiency syndrome (aids). treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note. it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life threatening candida infections. until such data are available, amphotericin b remains the drug of choice. vaginal candidiasis, when topical therapy has failed. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks